07:08 AM EDT, 03/26/2026 (MT Newswires) -- Kodiak Sciences ( KOD ) said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.

The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.

The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences ( KOD ) said.

The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.

Kodiak Sciences ( KOD ) added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.

Based on the results, Kodiak Sciences ( KOD ) said tarcocimab now has a multi-indication biologics license application-ready profile and the company plans to accelerate its submission timeline.

Shares of Kodiak Sciences ( KOD ) were up over 34% in premarket trading Thursday.

Price: 30.55, Change: +7.80, Percent Change: +34.29